Numab
PrivateLast Round
Series C
Extension
Jan 9, 2025
Total Funding Raised
$187.6M
Momentum Score
25 /100
Company Overview
Numab Drug Innovators is a biopharmaceutical company focused on developing multispecific antibody-based immunotherapies that streamline the discovery process to create tailored biotherapeutics for chronic inflammation and cancer.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials
Business Model
B2B
Customer Profile
Revenue Share
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Numab Comps
Public and private peers based on sector, stage, and business model.
Numab Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series C Extension | Jan 9, 2025 | ||||
| Series C | May 20, 2021 | ||||
| Series B | Mar 9, 2020 |
Key People
Founding team and executive leadership
Numab Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Forbion | Series C Extension |
| Octagon Capital Advisors | Series C Extension, Series C |
| Flerie Invest | Series C Extension, Series C |
| HBM Healthcare Investments | Series C Extension |
| Novo Holdings | Series C Extension, Series C |
| BVF Partners L.P. | Series C Extension, Series C |
| Octagon Capital Advisors | Series C Extension |
Market signals
Structured signals derived from secondary market and firmographic data.
- Sep 25, 2025
Achieved an unspecified milestone in collaboration with Boehringer Ingelheim.
- Sep 9, 2025
Barbara Angehrn Pavik appointed as new CEO and Board member.
Numab Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about Numab's valuation, stock price, and market status.
